C. Argentino

Growth advantage of chronic myeloid leukemia CFU-GM in vitro: survival to growth factor deprivation, possibly related to autocrine stimulation, is a more common feature than hypersensitivity to GM-CSF/IL3 and is efficiently counteracted by retinoids ± α-interferon

A. Pileri, D. Ferrero, C. Rus, 2001, Leukemia.

An analysis of which subgroups of multiple myeloma patients, divided according to b(2)-microglobulin and plasma cell labeling index, benefit from high dose vs conventional chemotherapy.

A. Palumbo, S. Molica, M. Boccadoro, 1999, Haematologica.

Treatment of bisphosphonate-related osteonecrosis using platelet-rich plasma: microtomographic, microscopic, and immunohistochemical analyses.

O. Ferreira Júnior, M. Matsumoto, M. Curi, 2019, Brazilian oral research.

Standard Treatment in Elderly Myeloma Patients Dose-Intensive Melphalan With Stem Cell Support (MEL100) Is Superior to

A. Palumbo, M. Boccadoro, A. Pileri, 2010 .

Dose-intensive melphalan with stem cell support (MEL100) is superior to standard treatment in elderly myeloma patients.

M. Boccadoro, A. Pileri, S. Bringhen, 1999, Blood.

Overweight as an adverse prognostic factor for non-Hodgkin's lymphoma patients receiving high-dose chemotherapy and autograft

A. Pileri, C. Magnani, D. Caracciolo, 2000, Bone Marrow Transplantation.